β-AR Polymorphisms and Glycemic and Lipid Parameters in Hypertensive Individuals Receiving Carvedilol or Metoprolol | Zendy

Orly Vardeny | Zendy; Gabriel Nicholas | Zendy; Alina Andrei | Zendy; Kevin A. Buhr | Zendy; Matt P. Hermanson | Zendy; John J. Moran | Zendy; Michelle A. Detry | Zendy; James H. Stein | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

β-AR Polymorphisms and Glycemic and Lipid Parameters in Hypertensive Individuals Receiving Carvedilol or Metoprolol

Author(s) -

Orly Vardeny,

Gabriel Nicholas,

Alina Andrei,

Kevin A. Buhr,

Matt P. Hermanson,

John J. Moran,

Michelle A. Detry,

James H. Stein

Publication year - 2012

Publication title -

american journal of hypertension

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.009

H-Index - 136

eISSN - 1941-7225

pISSN - 0895-7061

DOI - 10.1038/ajh.2012.54

Subject(s) - metoprolol , medicine , carvedilol , single nucleotide polymorphism , insulin , endocrinology , lipid profile , snp , insulin resistance , genotype , glycemic , diabetes mellitus , pharmacology , genetics , biology , heart failure , gene

β-Blocker therapy and β-adrenergic receptor (β-AR) polymorphisms are associated with increases in glucose and lipid levels. We investigated associations of common β1 and β2-AR single-nucleotide polymorphisms (SNPs) with metabolic and lipid variables, and examined interactions with β-blocker treatment assignment to affect these parameters.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research